Studies evaluating the possible correlation between clinical endpoints and polymorphisms of SLC22A1, OCTN1, OATP1A2 and CYP3A5 genes, their mRNA levels or transporter activity in CML patients treated with imatinib. Here, CYP3A5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.